Clinical Trials

The study is a Phase III, Placebo-controlled, Randomized, Observer-blinded, Multi-national, Multi-center Study to Assess the Safety, Reactogenicity, and Immunogenicity of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) adjuvanted with AS03 in Adults Aged 18 Years and Older.

Infants and young children are at increased risk for respiratory syncytial virus (RSV) infections because of their maturing immune system and lack of prior exposure to RSV. A genetically stable live-attenuated RSV ΔNS2/Δ1313/I1314L vaccine (from the US National Institutes of Health) has been

This research constitutes the long-term follow-up of participants enrolled in our Oral Cholera Vaccine Simplified (OCV-S) study conducted two years ago. During the OCV-S study, participants were administered either Euvichol-S or ShancholTM vaccines. In this observational study, a single

A Parallel-Group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV – 2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older’’

The purpose of this study is to evaluate the safety and effectiveness of Ketotifen and Indomethacin taken together to improve symptoms related with COVID-19. Ketotifen and Indomethacin are medications approved to treat diseases other than COVID-19.

This is a multicenter, randomized, observer-blinded, controlled study to evaluate immune non-inferiority and safety of OCV-S compared to Shanchol™ in 1 to 40 years old healthy Nepalese participants with the study period of 13 months duration.

Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial